Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior

Journal of Gastrointestinal Surgery

Volumn 7, Issue 8, 2003, Pages 1004-1014

  House, Michael G ^a,b   Guo, Mingzhou ^b   Efron, David T ^a   Lillemoe, Keith D ^a   Cameron, John L ^a   Syphard, James E ^c   Hooker, Craig M ^b   Abraham, Susan C ^a   Montgomery, Elizabeth A ^a   Herman, James G ^b   Brock, Malcolm V ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Division of Tumor Biology ^*

Author keywords

GIST; Methylation; Tumor suppressor genes

Indexed keywords

APC PROTEIN; DEATH ASSOCIATED PROTEIN KINASE; PROTEIN; PROTEIN ER; PROTEIN MGMT; PROTEIN MLH1; PROTEIN P16; PROTEIN P73; PROTEIN RAR BETA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; CANCER MORTALITY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; METHYLATION; MITOSIS RATE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 10744229661     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gassur.2003.08.002     Document Type: Conference Paper

References (43)

1. Trupiano J.K., Stewart R.E., Misick C., Appelman H.D., Goldblum J.R. Gastric stromal tumors: A clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors. Am J Surg Pathol. 26:2002;705-714.
2. Singer S., Rubin B.P., Lux M.L., Chen C.J., Demetri G.D., Fletcher C.D., Fletcher J.A. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 20:2002;3898-3905.
3. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., Silberman S., Capdeville R., Dimitrijevic S., Druker B., Demetri G.D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 344:2001;1052-1056.
4. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., Lydon N.B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 295:2000;139-145.
5. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D., Fletcher C.D., Fletcher J.A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:2003;708-710.
6. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., Hibbard M.K., Chen C.J., Xiao S., Tuveson D.A., Demetri G.D., Fletcher C.D., Fletcher J.A. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:2001;8118-8121.
7. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat Genet. 21:1999;163-167.
8. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., Strouboulis J., Wolffe A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet. 19:1998;187-191.
9. Antequera F., Boyes J., Bird A. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell. 62:1990;503-514.
10. Li E., Beard C., Jaenisch R. Role for DNA methylation in genomic imprinting. Nature. 366:1993;362-365.
11. Steenman M.J., Rainier S., Dobry C.J., Grundy P., Horon I.L., Feinberg A.P. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet. 7:1994;433-439.
12. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res. 72:1998;141-196.
13. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.P., Markowitz S., Willson J.K., Hamilton S.R., Kinzler K.W., Kane M.F., Kolodner R.D., Vogelstein B., Kunkel T.A., Baylin S.B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 95:1998;6870-6875.
14. Caca K., Feisthammel J., Klee K., Tannapfel A., Witzigmann H., Wittekind C., Mossner J., Berr F. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int J Cancer. 97:2002;481-488.
15. Belinsky S.A., Nikula K.J., Palmisano W.A., Michels R., Saccomanno G., Gabrielson E., Baylin S.B., Herman J.G. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 95:1998;11891-11896.
16. Ueki T., Toyota M., Sohn T., Yeo C.J., Issa J.P., Hruban R.H., Goggins M. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 60:2000;1835-1839.
17. Ueki T., Toyota M., Skinner H., Walter K.M., Yeo C.J., Issa J.P., Hruban R.H., Goggins M. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res. 61:2001;8540-8546.
18. Baek M.J., Kang H., Kim S.E., Park J.H., Lee J.S., Paik Y.K., Kim H. Expression of hMLH1 is inactivated in the gastric adenomas with enhanced microsatellite instability. Br J Cancer. 85:2001;1147-1152.
19. Cunningham J.M., Christensen E.R., Tester D.J., Kim C.Y., Roche P.C., Burgart L.J., Thibodeau S.N. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 58:1998;3455-3460.
20. Huang T.H., Perry M.R., Laux D.E. Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet. 8:1999;459-470.
21. Newman P.L., Wadden C., Fletcher C.D. Gastrointestinal stromal tumours: Correlation of immunophenotype with clinicopathological features. J Pathol. 164:1991;107-117.
22. Suster S., Sorace D., Moran C.A. Gastrointestinal stromal tumors with prominent myxoid matrix. Clinicopathologic, immunohistochemical, and ultrastructural study of nine cases of a distinctive morphologic variant of myogenic stromal tumor. Am J Surg Pathol. 19:1995;59-70.
23. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S.B., Herman J.G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59:1999;67-70.
24. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 93:1996;9821-9826.
25. Palmisano W.A., Divine K.K., Saccomanno G., Gilliland F.D., Baylin S.B., Herman J.G., Belinsky S.A. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60:2000;5954-5958.
26. House M.G., Guo M., Iacobuzio-Donahue C., Herman J.G. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis. 24:2003;193-198.
27. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
28. Peto R., Peto R. Asymptomatically efficient rank invariant test procedures. J R Stat Soc. 34:1972;185-206.
29. Larsen F., Gundersen G., Lopez R., Prydz H. CpG islands as gene markers in the human genome. Genomics. 13:1992;1095-1107.
30. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 61:2001;3225-3229.
31. DeMatteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., Brennan M.F. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg. 231:2000;51-58.
32. Miettinen M., Sarlomo-Rikala M., Lasota J. Gastrointestinal stromal tumors: Recent advances in understanding of their biology. Hum Pathol. 30:1999;1213-1220.
33. Sandberg A.A., Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma. Cancer Genet Cytogenet. 133:2002;1-23.
34. Barratt P.L., Seymour M.T., Stenning S.P., Georgiades I., Walker C., Birbeck K., Quirke P. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: A molecular study. Lancet. 360:2002;1381-1391.
35. Samowitz W.S., Curtin K., Ma K.N., Schaffer D., Coleman L.W., Leppert M., Slattery M.L. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 10:2001;917-923.
36. Okuyama T., Maehara Y., Kabashima A., Takahashi I., Kakeji Y., Sugimachi K. Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma. Oncology. 63:2002;353-361.
37. Font A., Abad A., Monzo M., Sanchez J.J., Guillot M., Manzano J.L., Pinol M., Ojanguren I., Rosell R. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum. 44:2001;549-557.
38. Esteller M., Gonzalez S., Risques R.A., Marcuello E., Mangues R., Germa J.R., Herman J.G., Capella G., Peinado M.A. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol. 19:2001;299-304.
39. Pajkos G., Kiss I., Sandor J., Ember I., Kishazi P. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res. 12:2000;1695-1701.
40. Park T.J., Han S.U., Cho Y.K., Paik W.K., Kim Y.B., Lim I.K. Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer. 92:2001;2760-2768.
41. Perl A.K., Wilgenbus P., Dahl U., Semb H., Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 392:1998;190-193.
42. Hawkins N., Norrie M., Cheong K., Mokany E., Ku S.L., Meagher A., O'Connor T., Ward R. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 122:2002;1376-1387.
43. Furukawa T., Konishi F., Masubuchi S., Shitoh K., Nagai H., Tsukamoto T. Densely methylated MLH1 promoter correlates with decreased mRNA expression in sporadic colorectal cancers. Genes Chromosomes Cancer. 35:2002;1-10.